retinitis pigmentosa

Reactivating cones possibility in addressing RPGlucose entrapment in the retinal pigment epithelium is responsible for central vision loss in retinitis pigmentosa. Injecting wild-type rods into the eye to restore glucose transportation or injecting glucose into the subretinal space can facilitate cone regeneration.
Neuroprotective strategy primed for progress
Neuroprotective strategy primed for progressAdvancing methods for evaluating therapeutic response have fostered a new era in glaucoma neuroprotection in which promising candidates are already being investigated in clinical trials and others are poised to begin phase I testing, said Jeffrey L. Goldberg, MD, PhD.
Gene therapy trial launched for X-linked retinitis pigmentosaResearchers have injected their first patient with a virus engineered to remodel the gene responsible for X-linked retinitis pigmentosa (XLRP).
Retinal prosthesis offers hope to blind patientsAn artificial retinal prosthesis allows patient with retinitis pigmentosa (RP) to locate objects, detect movement, and improve orientation and mobility skills.
New wide-field, dual-array, suprachoroidal-transretinal stimulation prosthesis demonstrates surgical feasibilityProf. Fujikado presents his research, which demonstrated the surgical feasibility and safety of a newly developed, dual-array, suprachoroidal-transretinal stimulation prosthesis in animals. The dual-array design was able to activate retinal neurons and optic nerve axons. Findings indicate the future possibility of activating of a larger visual field with the prosthesis.
Experimental gene therapy shows promise for RPA new gene therapy could preserve vision in people with retinitis pigmentosa and might effectively treat other degenerative nerve disorders.
Trophic factor replacement targets most debilitating effects of RPDegeneration of rods in eyes with RP leads to night vision problems and loss of rod-derived cone viability factor (RdCVF) that is necessary for cone survival. Replacing RdCVF may prevent cone degeneration and loss of central vision.
Subretinal implant yields meaningful benefits for retinitis pigmentosaOne-year outcomes with a subretinal implant for patients blinded by retinitis pigmentosa demonstrated a marked improvement in visual capabilities.
FDA drug approvals-May 2015FDA actions in brief, complete response, breakthrough therapy designation, fast-track designations, orphan drug designations
Retinal gene therapy advancing into clinical realityGene therapy can provide transformative disease-modifying effects, with potentially lifelong clinical benefits after a single therapeutic administration. The most advanced retinal gene therapy program in the United States is in phase III study.